Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Falls 10.2% - Here's What Happened

Key Points

• Eupraxia Pharmaceuticals shares fell 10.2% to about $8.17 during Thursday trading, with volume down 67% from its average.
• Despite the decline, analysts maintain a generally positive view: the stock has a “Moderate Buy” consensus rating and an average price target of $17.80, well above its recent price.
• The company reported a quarterly loss of $0.23 per share, beating expectations by $0.02; analysts forecast a full-year loss of $0.85 per share, while several institutional investors recently initiated or increased positions.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s stock price was down 10.2% during trading on Thursday. The company traded as low as $8.20 and last traded at $8.1740. Approximately 103,276 shares changed hands during trading, a decline of 67% from the average daily volume of 316,450 shares. The stock had previously closed at $9.10.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on EPRX shares. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Thursday. Wedbush initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, September 24th. They set an "outperform" rating and a $17.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Stifel Nicolaus set a $25.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Finally, Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eupraxia Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $17.80.

Eupraxia Pharmaceuticals Stock Down 9.9%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00. The firm has a market capitalization of $533.10 million, a PE ratio of -8.00 and a beta of 1.07. The company has a fifty day moving average price of $7.31 and a 200-day moving average price of $7.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. As a group, analysts expect that Eupraxia Pharmaceuticals Inc. will post -0.85 earnings per share for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EPRX. AXQ Capital LP lifted its stake in shares of Eupraxia Pharmaceuticals by 34.2% in the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company's stock valued at $140,000 after purchasing an additional 5,390 shares during the last quarter. Seven Fleet Capital Management LP purchased a new stake in Eupraxia Pharmaceuticals during the 2nd quarter valued at $4,037,289. Bank of America Corp DE bought a new stake in Eupraxia Pharmaceuticals in the second quarter worth $1,750,000. Jupiter Topco LLC purchased a new position in Eupraxia Pharmaceuticals during the second quarter worth $6,851,000. Finally, Cibc World Market Inc. bought a new position in Eupraxia Pharmaceuticals during the second quarter valued at $1,539,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc NASDAQ: EPRX is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients' exposure to medication throughout the body.

Eupraxia's development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects.

The company's lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.